Injuria hepática inducida en pacientes tratados con antifímicos en una clínica de IV nivel de la ciudad de Barranquilla, Colombia en el año 2020
| datacite.rights | http://purl.org/coar/access_right/c_16ec | spa |
| dc.contributor.advisor | Cadena Bonfanti, Andre Angelo | |
| dc.contributor.author | Aconcha Montenegro, Julián Elías | |
| dc.contributor.author | Narváez Martínez, Carlos Wilson | |
| dc.date.accessioned | 2023-01-11T14:45:53Z | |
| dc.date.available | 2023-01-11T14:45:53Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | La tuberculosis es una infección de origen pulmonar con alta prevalencia en la población colombiana que ha traído consigo el requerimiento de manejo con medicamentos llamados antituberculosos (antifímicos) generando una respuesta favorable en nuestro paciente. Pero en muchas ocasiones este tipo de medicamentos generan daños tales como lesión hepática, intolerancia o reacciones adversas comúnmente documentadas en las personas que lo reciben. De las reacciones comúnmente como conocidas existe una que produce daño hepático inducido por fármacos por sus siglas en inglés “Drug Induced Liver Injury” (DILI). Objetivo: Evaluar DILI inducida por antifímicos en pacientes atendidos en una clínica de IV nivel de la ciudad de Barranquilla Colombia en el año 2020. Materiales y Métodos: Se realizó un estudio de cohorte observacional con estudio de casos, es común en el área de la medicina por ser estudios epidemiológicos. Se tomaron 61 pacientes diagnosticados con tuberculosis pulmonar (12 del grupo de estudio por presentar alteración por antifimicos y 61 grupo control) hospitalizados en la clínica de la costa durante el año 2020 en la ciudad de Barranquilla (Colombia). Los datos se organizaron en una base de Excel se realizó el análisis de estadística descriptiva con el programa Statistical Package for Social Sciences (SPSS). se caracterizó socio-demográficamente, clínica y farmacológicamente. Además, Establecer la asociación entre los factores de riesgo y/o comorbilidades y el tipo de injuria hepática. | spa |
| dc.description.abstract | Tuberculosis is an infection of pulmonary origin with a high prevalence in the Colombian population that has brought with it the requirement of management with drugs called antituberculosis (antiphyrics) generating a favorable response in our patient. But in many cases this type of medication generates damage such as liver injury, intolerance or commonly documented adverse reactions in people who receive it. Of the commonly known reactions there is one that produces drug-induced liver damage (DILI)". Objective: To evaluate antiphytic-induced DILI in patients treated in an IV-level clinic in the city of Barranquilla Colombia in 2020. Materials and Methods: We conducted an observational cohort study with case studies, it is common in the area of medicine as epidemiological studies. Sixty-one patients diagnosed with pulmonary tuberculosis (12 in the study group for presenting antiphymal alteration and 61 in the control group) were hospitalized in the coastal clinic during 2020 in the city of Barranquilla (Colombia). The data was organized in an Excel database and descriptive statistics analysis was performed with the program Statistical Package for Social Sciences (SPSS). was characterized socio-demographically, clinically and pharmacologically. In addition, establish the association between risk factors and/or comorbidities and the type of liver injury. | eng |
| dc.format.mimetype | spa | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/11678 | |
| dc.language.iso | spa | spa |
| dc.publisher | Ediciones Universidad Simón Bolívar | spa |
| dc.publisher | Facultad de Ciencias de la Salud | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/restrictedAccess | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | Antifimicos | spa |
| dc.subject | Comorbilidades DILI | spa |
| dc.subject | Injuria hepática | spa |
| dc.subject | Antiphymals | eng |
| dc.subject | DILI comorbidities | eng |
| dc.subject | Liver injury | eng |
| dc.title | Injuria hepática inducida en pacientes tratados con antifímicos en una clínica de IV nivel de la ciudad de Barranquilla, Colombia en el año 2020 | spa |
| dc.type.driver | info:eu-repo/semantics/other | spa |
| dc.type.spa | Otros | spa |
| dcterms.references | R. T. Stravitz and W. M. Lee, “Acute liver failure,” 2019. [Online]. Available: www.thelancet.com | spa |
| dcterms.references | V. Dong, R. Nanchal, and C. J. Karvellas, “Pathophysiology of Acute Liver Failure,” Nutrition in Clinical Practice, vol. 35, no. 1. John Wiley and Sons Inc., pp. 24–29, Feb. 01, 2020. doi: 10.1002/ncp.10459. | eng |
| dcterms.references | R. , Vuppalanchi, S. , Liangpunsakul, and N. Chalasani, “Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?.,” American Journal of Gastroenterology, vol. 102, no. 3, 2007. | eng |
| dcterms.references | L. Morales, N. Velez, and O. Muñoz, “Hepatotoxicidad: patrón colestásico inducido por fármacos,” Rev Colomb Gastroenterol, vol. 31, no. 1, pp. 36–47, 2016. | spa |
| dcterms.references | K. Tajiri and Y. Shimizu, “ Practical guidelines for diagnosis and early management of drug-induced liver injury. ,” World journal of gastroenterology: WJG, 14, vol. 14, no. 44, 2008. | eng |
| dcterms.references | M. Lucena, R. Andrade, Kaplowitz N, and García-Cortes M, “Phenotypic cha- racterization of idiosyncratic drug-induced liver injury: The influence of age and sex. ,” Hepatology, 2009. | eng |
| dcterms.references | P. Baghaei, P. Tabarsi, and E. Chitsaz, “ Incidence, Clinical and Epidemiological Risk Factors, and Outcome of Drug- Induced Hepatitis Due to Antituberculous Agents in New Tuberculosis Cases. ,” Am J Ther , pp. 17–22, 2010. | eng |
| dcterms.references | N. Chalasani and E. Björnsson, “ Risk Factors for Idiosyncratic Drug-Induced Liver Injury. ,” AGA Journals. 2010;138(7):2246–2259. , vol. 138, no. 7, pp. 2246–2259, 2010. | eng |
| dcterms.references | G. Derosa and P. Maffioli, “ Traditional Markers in Liver Disease. En V. R. Preedy (Ed.), Biomarkers in Liver Disease,” Netherlands: Springer Nature, vol. 1, p. 2012, 2017. | eng |
| dcterms.references | P. Y. Kwo, S. M. Cohen, and J. K. Lim, “ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries,” American Journal of Gastroenterology, vol. 112, no. 1, pp. 18–35, Jan. 2017, doi: 10.1038/ajg.2016.517. | eng |
| dcterms.references | R. Hernandez, C. Fernandez, and P. Baptista, Metodologia de investigaciòn, 7th ed., vol. 1. 2014. | spa |
| dcterms.references | H. Zhao, Y. Wang, T. Zhang, Q. Wang, and W. Xie, “Drug-induced liver injury from anti-tuberculosis treatment: A retrospective cohort study,” Medical Science Monitor, vol. 26, Mar. 2020, doi: 10.12659/MSM.920350. | eng |
| dcterms.references | M. D. R. Hernández Bendezú, “Factores asociados a severidad de la reacción adversa de tipo hepática a fármacos antituberculosos,” Centro Médico Naval , 2022. | spa |
| dcterms.references | T. Oscanoa, S. Moscol, and J. Amado, “Características clínicas de la hepatotoxicidad asociada a la pirazinamida en pacientes de un hospital de Lima, Perú,” Rev Peru Med Exp Salud Publica, vol. 37, no. 3, pp. 516–20, Sep. 2020, doi: 10.17843/rpmesp.2020.373.4684. | spa |
| oaire.version | info:eu-repo/semantics/acceptedVersion | spa |
| sb.programa | Especialización en Medicina Interna | spa |
| sb.sede | Sede Barranquilla | spa |